RealTime Dynamix: Rheumatoid Arthritis US (quarterly)

The US biologics and small molecule market for the treatment of rheumatoid arthritis (RA) is well established with a variety of drugs and mechanisms of action for treatment. Though the backbone TNF-inhibiting biologics have dominated the space for nearly two decades, more recent launches, an active pipeline, and the introduction of biosimilars present an opportunity for major future shifts in the RA landscape.

The RealTime Dynamix:™ Rheumatoid Arthritis (US) report series provides a detailed and timely look at current and future trends in the RA market and the effects of the future shifting landscape. The quarterly releases allow for close monitoring and trending of key performance metrics. In addition to the fixed trended measures, the report also includes variable content addressing key current issues updated quarterly. The rapid field-to-insight turnaround time, highly relevant content, and unparalleled knowledge of the rheumatology market make this an essential tool for companies competing in the space, as well as those with near-term plans to enter it.

The report is based on an online survey of ~100 US rheumatologists and is fielded on a quarterly basis. Respondents are recruited from the Spherix Network, a proprietary group of rheumatologists in clinical practice meeting quality screening criteria. Our relationship with this network leads to more engaged respondents resulting in higher quality output.

US Rheumatologists’ Early Views on Eli Lilly’s Olumiant for the Treatment of Rheumatoid Arthritis Show Uphill Battle, While Pfizer’s Xeljanz Holds Ground as the Preferred JAK Inhibitor – August 20, 2018>VIEW ARTICLE

Join Our Newsletter

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit About Cookies page.OKREAD MORE